- Madlen Hubert becomes newly promoted Associate Professor!
- Madlen Hubert receives grant from the Valborg Jacobsons fond
- Now hiring: Two PhD Students in Molecular Pharmaceutics
- ***Update – Symposium will be held online***
- New article from the group was selected as today's ACS American Chemical Society Editors' Choice!
Liu, Kang-Cheng; Pace, Hudson; Larsson, Elin; Hossain, Md Shakhawath; Kabedev, Aleksei; Shukla, Ankita; Jerschabek, Vanessa; Mohan, Jagan; Bergström, Christel; Bally, Marta; Schwieger, Christian; Hubert, Madlen; Lundmark, Richard
Membrane insertion mechanism of the caveola coat protein Cavin1
Berg, Staffan; Suljovic, Denny; Kärrberg, Lillevi; Englund, Maria; Bönisch, Heiko; Karlberg, Ida; Van Zuydam, Natalie; Abrahamsson, Bertil; Hugerth, Andreas Martin; Davies, Nigel; Bergström, Christel A. S.
Intestinal Absorption of FITC-Dextrans and Macromolecular Model Drugs in the Rat Intestinal Instillation Model
Ansari, Shaquib; Hempel, Nele-Johanna; Asad, Shno; Svedlindh, Peter; Bergström, Christel; Lobmann, Korbinian; Teleki, Alexandra
Hyperthermia-Induced In Situ Drug Amorphization by Superparamagnetic Nanoparticles in Oral Dosage Forms
We have a strong interest in understanding the molecular reasons resulting in a poor aqueous solubility and have established tools for computational pharmaceutics that guide the formulation scientists in successful development pathways for a particular compound. We are currently developing a virtual intestine to enable evaluation optimization of new dosage forms in the computer rather than making use of lengthy experiments or animal studies.
Our research in the field of poorly soluble compounds is extensively based on drug dissolution & permeation studies to predict e.g. intestinal solubility. The research team also focuses on the development of sophisticated dosage forms that transforms problematic compounds (poorly soluble, biologics) into well-functioning oral medications.
Enabling formulations making use of lipid-based formulations, amorphous materials, mesoporous carriers and functionalized drug carriers are currently being explored. Additive manufacturing and 3D printing to produce personalized medicines to improve treatment and quality of life of severely sick children is one of our main targets.